2Davis T A,Grillo Lopez A J,Wite C A,et al.Rituximab anti-CD20 monoclonal antibody therapy in non-hodgkin's lymphoma;safety and efficacy of re-treatment[J].J Clin Oncol,2000,18(17):3135-3143.
3E1is A,Blickstein D,Klein O,et al.Detection of relapse in non-Hodgkin's lymphoma;role of routine follow-up studies[J].AmJ Hematol,2002,69(1):41-44.
4Czuczman M S,Fallon A,Mohr A,et al.Rituximab in combination with CHOP or fludarabine in low-grade lymphoma[J].Oncol,2002,29(1 Suppl 2):36-40.
5Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J].N Engl J Med,2002,346(4):235-242.
6Vose J M,Link B K,Grossbard M L,et al.Phase Ⅱ study of Rituximab in com bin ation with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389-397.
二级参考文献14
1Landis S, Murray T, Bolden S, et al. Cancer statistics[J]. CA Cancer J Clin, 1998, 48(1): 6-29.
2Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994, 83(2): 435-445.
3Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody[J]. J Immumol, 1990, 144(4): 1382-1386.
4Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20(IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J]. Cancer Biother Radiopharm, 1997, 12(3): 177-186.
5Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomised trial from the Lymphoma Group of Central Sweden[J]. Ann Oncol, 1994, 5(Suppl 2): S67-S71.
6Berinstein NL, Grillo Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C21B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hedgkin's lymphoma[J]. Ann Oncol, 1998, 9(9): 995-1001.
7McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program [J]. J Clin Oncol, 1998, 16(8): 2825-2833.
8Maloney KG, Liles TM, Czerwinski DK, et al. Phase Ⅰ clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma[J]. Blood, 1994, 84: 2457-2466.
9Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion[J]. Blood ,2000, 96(3): 864-869.
10Gribben JG, Neuberg D, Freesman AS, et al. Detection by polymerase chain in reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma[J]. Blood, 1993, 81(12): 3449-3457.
